Updated Results of Rituximab Pre- and Post-BEAM with or without Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.

Clin Cancer Res 2018 05 23;24(10):2304-2311. Epub 2018 Feb 23.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.

We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan (YIT) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem cell transplant (ASCT). Patients were enrolled on three consecutive phase II clinical trials. Patients received two doses of rituximab (375 and 1,000 mg/m) during mobilization of stem cells, followed by 1,000 mg/m on days +1 and +8 after ASCT with R-BEAM or YIT-R-BEAM (YIT dose of 0.4 mCi/kg) conditioning. One hundred thirteen patients were enrolled, with 73 receiving R-BEAM and 40 receiving YIT-R-BEAM. All patients had a prior exposure to rituximab. The median follow-up intervals for survivors were 11.8, 8.1, and 4.2 years in the three trials, respectively. The 5-year disease-free survival (DFS) rates were 62% for R-BEAM and 65% for YIT-R-BEAM ( = 0.82). The 5-year overall survival rates were 73% and 77%, respectively ( = 0.65). In patients with DLBCL, survival outcomes of the germinal center/activated b-cell histologic subtypes were similar with 5-year OS rates ( = 0.52) and DFS rates ( = 0.64), irrespective of their time of relapse (<1 vs. >1 year) after initial induction chemotherapy ( = 0.97). Administering ASCT with rituximab during stem cell collection and immediately after transplantation induces long-term disease remission and abolishes the negative prognostic impact of cell-of-origin in patients with relapsed DLBCL. The addition of YIT does not confer a further survival benefit. .

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-3561DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955837PMC
May 2018
36 Reads

Publication Analysis

Top Keywords

diffuse large
8
stem cell
8
large b-cell
8
b-cell lymphoma
8
patients enrolled
8
ibritumomab tiuxetan
8
dfs rates
8
patients relapsed
8
1000 mg/m
8
patients
7
survival
5
5-year disease-free
4
trials 5-year
4
73% 77%
4
years three
4
three trials
4
survival rates
4
rates 73%
4
survival dfs
4
5-year survival
4

Similar Publications